Gleb Kuznetsov’s Post

Here's the link to a very simple agent on a clinical graph I presented: https://lnkd.in/eeKTZKaT

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Technology. The 2024 Impact Award, sponsored by InterSystems, acknowledges BioStrand’s innovative LENSᵃⁱ technology, selected from over 1,000 client projects for its remarkable contributions. The selection committee, chaired by Professor Roberto Zicari, identified BioStrand’s work based on three key criteria: makes a significant difference, breaks new ground and sets an example. Tune in to today's Main Stage live to see the award presentation from 10:30-11:00am ET : https://bit.ly/3RtxGGP See the full release: https://bit.ly/3RonJur #GlobalSummit24 #TechBio #VectorSearch #DrugDiscovery #Biotech #ArtificialIntelligence #Antibodies #OmicsData BioStrand (a subsidiary of IPA)

The agenda for BioTechX USA 2024 is now LIVE 🚨🎉 ... but spaces are filling up fast! If you're looking to present in front of decision-makers from top-30 BioPharma and Biotechs, please get in touch. 📧 Joshua.Kennedy@Terrapinn.com 📞 +44 208 156 5877 #digitaltransformation #pharma #biopharma #startup #ai #mach #llm #bigdata

🌟 Sanofi x AQEMIA: Redefining the way new medicines are developed, atom by atom 🌟 Together, we aim to redefine the way new medicines are developed, accelerating the delivery of innovative treatments to patients. By combining Sanofi’s R&D expertise with AQEMIA’s physics-powered algorithms, our partnership is pioneering the design and optimization of molecules with unparalleled speed and precision. In this conversation, Matt Truppo (Sanofi’s Global Head of Research Platforms & Computational R&D) and Maximilien Levesque (AQEMIA CEO & Cofounder) discuss how this unique collaboration is accelerating progress in drug discovery. Watch the full discussion below ⤵ #Biotech #GenAI #DrugDiscovery

CAS BioFinder saves you time, mitigates risks, and accelerates your drug discovery program. Working through the literature to find disease targets, plan structure-activity-relationship studies, and assess the potential for off-target interactions takes time and risks missing key information. With CAS BioFinder, you can quickly access the verified data you need along with predicted bioactivity values, all derived from the existing literature—ensuring confidence that you always have the most relevant results. Our expert scientists have combed through the literature and patents, extracted information relevant to drug discovery scientists, and connected related data points so that you can quickly answer your drug discovery questions. This commitment to manual curation by CAS experts means you can trust the quality of the insights you uncover. Leverage existing and predicted bioactivity, ligand, sequence, and biomarker data, all accessible from the streamlined CAS BioFinder user interface, to save time and accelerate your drug discovery program.

Such a strong group of co-investors in TIAP portfolio company AmacaThera — a clinical-stage #biotech company developing a novel #drugdelivery platform to improve patient outcomes across multiple therapeutic areas — co-founded by the University of Toronto's Drs. Molly Shoichet and Mike Cooke. Find out more about AmacaThera and TIAP's diverse portfolio of 70+ companies at: https://tiap.ca/portfolio/ #OIS2024 #OBIOInvestmentSummit #OBIOInvestmentSummit2024

What are the challenges facing European biotech right now? Ekin Ece Erkan Kaplan shares her perspectives for this IBTV Movers & Shakers interview at Advanced Therapies Europe 👇 #ATE24 #Biotech

Discover the latest trends and innovations shaping the future of biotechnology from #BIO2024! From psychedelics to AI in drug discovery, learn what we saw and heard about how the industry is navigating challenges and driving change.   Read more here: https://bit.ly/3VGD0rJ   #Biotech #HealthcareInnovation #BIO2024Insights #HealthcareComms #InizioEvokeComms

I am happy to share that our paper on CavitOmiX drug discovery was published last week in a special issue "Antivirals against Arboviruses" Viruses MDPI! 😊 At Innophore, we are dedicated to advancing computational tools for faster and safer drug development. Our CavitOmiX copilot, an in-silico side-effect screening platform developed in collaboration with NVIDIA, rapidly identifies potential off-target sites in the human organism based on binding-site similarities. Addressing potential side effects early in the drug-development process is crucial, as up to 30% of clinical trials fail due to unfavorable toxicity profiles 💊 Innophore's Catalophore technology facilitates drug repurposing strategies and early off-target site screening, enabling the refinement of drugs for improved binding to drug-target sites and reduced binding to potential off-target sites. Discover in our latest article how we tackle these drug-discovery challenges 📝 https://lnkd.in/deQsGQSB Big thanks to all co-authors for the great teamwork! 🤗 Christian C. Gruber Andreas Krassnigg Michael Christian Hetmann Anna Hofmann Karl Gruber Georg Steinkellner #Innophore #CavitOmiX #DrugDiscovery #Research #Innovation #MDPI #GrazUniversity #PyMOL3

TechBio is impacting the drug discovery process in different ways. Our corporate development manager Cam Watson was on the panel at ON Helix 2024. The discussion was generally focused around how there are more ways for drug discovery to use data in their approaches. This is allowing drug discovery to proceed more efficiently and identify new and exciting opportunities – including discovering how drugs can work in completely new ways or finding new targets altogether. Cam highlighted the importance in TechBio of bringing these insights into the real world and that technologies like our eProtein discovery™ were absolutely critical in this. “The really exciting aspect about TechBio”, Cam highlighted, “is that it’s making engineering biology more accessible and decentralized, meaning more people can engage with it and develop their own hypothesis.” Want to learn how we're changing the drug development game? Click the link ➡ http://eprote.in/fYj1zdI3 #ONHelix24 #proteinacess #drugdiscovery